Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:2299:263-274.
doi: 10.1007/978-1-0716-1382-5_19.

Fibrosis on a Chip for Screening of Anti-Fibrosis Drugs

Mohammadnabi Asmani  1 , Ruogang Zhao  2
Affiliations

Fibrosis on a Chip for Screening of Anti-Fibrosis Drugs

Mohammadnabi Asmani et al. Methods Mol Biol. 2021.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic pathological disorder that targets alveoli interstitial tissues and is characterized by the progressive stiffening of alveolar membrane. The median survival rate of the patients with IPF is less than 5 years. Currently, IPF has no cure and there are few options to alleviate the progress of this disease. A critical roadblock in developing new anti-fibrosis therapies is the absence of reliable cell based in vitro models that can recapitulate the progressive features of this disease. Here a novel fibrotic microtissue on a chip system is created to model the fibrotic transition of the lung interstitial tissue and the effect of anti-fibrosis drugs on such transitions. This system will not only help to expedite the efficacy analysis of anti-fibrotic therapies but also help to unveil their potential mode of action.

Keywords: Anti-fibrosis therapy; Drug screening; Lung on a chip; Microtissue array; Nintedanib; Pirfenidone; Pulmonary fibrosis; Stiffness, and contractile force; Tissue mechanics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028. https://doi.org/10.1038/nm.2807 - DOI - PubMed - PMC
    1. Friedman S, Sheppard D, Duffield J, Violette S (2013) Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 5:167sr1. https://doi.org/10.1126/scitranslmed.3004700 - DOI - PubMed
    1. King TE, Pardo A, Selman M (2011) Idiopathic pulmonary fibrosis. Lancet 378:1949. https://doi.org/10.1016/S0140-6736(11)60052-4 - DOI - PubMed
    1. Hinz B (2012) Mechanical aspects of lung fibrosis: a spotlight on the myofibroblast. Proc Am Thorac Soc 9:137. https://doi.org/10.1513/pats.201202-017AW - DOI - PubMed
    1. Ebihara T, Venkatesan N, Tanaka R, Ludwig MS (2000) Changes in extracellular matrix and tissue viscoelasticity in bleomycin-induced lung fibrosis. Temporal aspects. Am J Respir Crit Care Med 162:1569. https://doi.org/10.1164/ajrccm.162.4.9912011 - DOI - PubMed

LinkOut - more resources